Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter
about
Early implementation of QbD in biopharmaceutical development: a practical exampleImproving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsProtein aggregation and its impact on product qualityAdvances in Antibody DesignRole of anisotropic interactions for proteins and patchy nanoparticles.Structure based descriptors for the estimation of colloidal interactions and protein aggregation propensitiesIn silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.Critical examination of the colloidal particle model of globular proteinsThe limitations of an exclusively colloidal view of protein solution hydrodynamics and rheology.Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies.Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product developmentHigh-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions.Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.A novel screening method to assess developability of antibody-like molecules.High concentration biotherapeutic formulation and ultrafiltration: Part 1 pressure limits.Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.Influence of structure properties on protein-protein interactions-QSAR modeling of changes in diffusion coefficients.Colloidal Stability & Conformational Changes in β-Lactoglobulin: Unfolding to Self-AssemblyIntermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions.Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.High throughput detection of antibody self-interaction by bio-layer interferometry.Characterization of highly concentrated antibody solution - A toolbox for the description of protein long-term solution stabilityCharge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.Challenges in Predicting Protein-Protein Interactions from Measurements of Molecular DiffusivityRational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.Both protein adsorption and aggregation contribute to shear yielding and viscosity increase in protein solutions.Intrinsically disordered sequences enable modulation of protein phase separation through distributed tyrosine motifs.Predicting protein-protein interactions of concentrated antibody solutions using dilute solution data and coarse-grained molecular models.Viscosity Control of Protein Solution by Small Solutes: A Review.Characterizing protein-protein-interaction in high-concentration monoclonal antibody systems with the quartz crystal microbalance.Viscosity Analysis of Dual Variable Domain Immunoglobulin Protein Solutions: Role of Size, Electroviscous Effect and Protein-Protein Interactions.Quantitative Correlation between Viscosity of Concentrated MAb Solutions and Particle Size Parameters Obtained from Small-Angle X-ray Scattering.Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.Charge Shielding Prevents Aggregation of Supercharged GFP Variants at High Protein Concentration.Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties.MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.
P2860
Q26830466-A5F160DA-684E-4D05-AD50-BB3EF46B8744Q27002558-D21F509E-B214-4FF7-9898-24245DD2F078Q27010661-EB487F51-83AC-4C0D-A8FF-52154E52C725Q28817608-D17FDFE0-D7AD-4D1B-8F48-5AFDC476CAE9Q34481834-FDAC3AE9-CE15-425C-B1DD-37B6027E8619Q34658019-641F3866-ED47-41DA-A80F-9466855A9262Q34831383-F6D20527-4153-4C1E-BDE3-0D964B8F340AQ35050644-A51AF437-74CB-4B24-8092-3EC7F18B5B56Q37338052-221C5120-11F1-4576-8D62-949771574EAFQ38313350-3D454425-EC17-47E8-A210-371C7289D8AFQ38652096-31A9B914-5C1C-485D-A068-0A844BE3A99CQ38688235-AE3D004F-2DA7-49D9-BDE0-CF7CCD04B632Q38718094-C385B844-BDC7-4BD9-AC62-51FD9EA02421Q38765564-65598A7B-7D30-4F60-9D64-56F685C888A5Q38783040-610D63CF-CF8A-418D-AA18-35BA94D2FE8EQ38876656-35AB9C59-D26B-4F4B-95B9-95D9AFACCC39Q38906930-E3982378-C133-421C-ABC8-059A74F3947BQ39066090-7098C82E-ED75-4D77-8599-80042DB10CE5Q39228104-41A0B3B5-B908-4C73-BF77-5954DC3CA8E6Q40654144-775D00F9-49BF-4B02-AD9F-416C4D95A0CFQ41127186-260B4BB1-BA68-4A8B-A5E7-E4785E1F2BEDQ41596017-9FC7D277-F622-4A25-8BFD-89D145D768C4Q41845586-E6043C85-A237-4A4A-B496-5F3DDF4832F2Q41880645-5F6D2EB3-06EE-4CC6-8ADB-D6CCDC56C022Q42111378-029179C3-C2DA-4068-BD79-7F8016888724Q42129206-30BEB11D-E8FE-42B3-AAF8-D00F9C86FB7EQ42601309-021463DB-E289-405A-A581-51AC91162A56Q42693191-9EA36589-CA08-4477-8F9A-36C43B2CC2BFQ43199562-C01B7A77-66C0-4566-8C51-8AA50504EF5BQ44796408-B2C82B31-F65B-406E-8399-A7E9DE0FD735Q47137715-4532434C-D36F-4DDD-84DF-7BBF3BDF9CA5Q47221856-6B25F222-0699-4C0D-B881-3CE52091C599Q47297020-EA29F918-CFF2-48D9-B3FA-44230A984436Q47336739-DA8F4B3C-717B-41D2-8E75-671A26A9E2EAQ47367882-5728E40B-FA61-4604-89CF-27427905FD91Q47380764-EBBD2EC0-463B-4E87-80B2-8457896AAD7CQ47693273-E8B9E322-4C89-459F-84C6-B4C95D9B0F9AQ47718842-351649C7-4026-4C67-8E5A-B2D9B6F1A7EEQ51080917-D2917BA8-7EA3-4C38-875C-6F10EB80FBC6Q51084133-EB11CD6F-012A-4ADC-A1B0-D7183BF5CDD0
P2860
Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Weak interactions govern the v ...... iffusion interaction parameter
@en
Weak interactions govern the v ...... iffusion interaction parameter
@nl
type
label
Weak interactions govern the v ...... iffusion interaction parameter
@en
Weak interactions govern the v ...... iffusion interaction parameter
@nl
prefLabel
Weak interactions govern the v ...... iffusion interaction parameter
@en
Weak interactions govern the v ...... iffusion interaction parameter
@nl
P2093
P2860
P1433
P1476
Weak interactions govern the v ...... iffusion interaction parameter
@en
P2093
Barthélemy Demeule
Brian D Connolly
Chris Petry
Jamie M R Moore
Natalie Ciaccio
Sandeep Yadav
Steven J Shire
Yatin R Gokarn
P2860
P356
10.1016/J.BPJ.2012.04.047
P407
P577
2012-07-01T00:00:00Z